<DOC>
	<DOCNO>NCT02581423</DOCNO>
	<brief_summary>This study evaluate safety tolerability capecitabine ( Xeloda ) participants undergone surgery colon cancer . Oral Xeloda administer twice daily 3-week cycle total 8 cycle . The anticipated time study treatment 24 week , target sample size 70 individual .</brief_summary>
	<brief_title>A Study Capecitabine ( Xeloda ) Adjuvant Treatment Participants With Resected Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adults least 18 year age Curative surgery Stage III colon cancer , perform 4 8 week study entry Macroscopic microscopic residual tumor Evidence metastatic disease include tumor cell ascites Previous cytotoxic chemotherapy , radiotherapy , immunotherapy colon cancer Active cardiovascular disease Other malignancy within last 5 year , curatively treat basal cell cancer skin situ cancer cervix Malabsorption syndrome lack physical integrity upper gastrointestinal tract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>